EUVIMEDEUVIMED entdecken
Crossref

Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis

Joshua Bomsztyk iD, Sriram Ravichandran iD, Hannah V Giles, Nicola Wright, Oscar Berlanga iD, Jahanzaib Khwaja iD, Shameem Mahmood, Brendan Wisniowski, Oliver Cohen, Darren Foard, Janet Gilbertson, Muhammad U Rauf iD und 11 weitere

Blood · 28.03.2024 · 143 (13) · 1259-1268

DOI: 10.1182/blood.2023022399 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 28.03.2024. Verfasst von Joshua Bomsztyk und 22 weiteren Autor:innen. Beteiligte Einrichtung: National Amyloid Centre, Royal Free Hospital, London, United Kingdom. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Amyloidosis. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amyloidogenic serum free light chains (sFLCs) drive disease progression in AL amyloidosis. Matrix-assisted laser desorption/ionization time of flight mass spectrometry–based FLC assay (FLC-MS) has greater sensitivity than conventional sFLC assays allowing for the detection of serological residual disease. We report the utility of FLC-MS in a large series of patients with AL amyloidosis assessing the impact of FLC-MS negativity after treatment on overall survival (OS) and organ response rates. Serum samples were analyzed using FLC-MS at diagnosis and at 6 and 12 months after treatment. The impact of FLC-MS negativity over standard hematologic responses on survival and organ response was assessed. A total of 487 patients were included; 290 (59%) and 349 (71.5%) had cardiac and renal involvement, respectively. There was 100% concordance between the light chain (LC) fibril type and LC isotype identified by FLC-MS. At 6 and 12 months, 81 (16.6%) and 101 (20.7%) were FLC-MS negative. Of those achieving a conventional hematologic complete response (CR) at 6 and 12 months, 45 (27.7%) and 64 (39%) were FLC-MS negative. At 12 months, median OS for CR + FLC-MS negative was not reached vs 108 months in CR + FLC-MS positive (P = .024). At 12 months, 70% of patients with FLC-MS negativity (vs 50% FLC-MS positive) achieved a cardiac response (P = .015). In a multivariate analysis, FLC-MS negativity at 12 months was an independent predictor of better outcomes. FLC-MS can detect persistent monoclonal light chains in a significant proportion of patients in a conventional hematologic CR. FLC-MS assessment promises to be a new standard for response assessment in AL amyloidosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin Light-chain AmyloidosisAmyloidosisHumansImmunoglobulin Light ChainsPathologic Complete ResponseDisease Progression

Substanzen

Immunoglobulin Light Chains

Autor:innen und Institutionen

  • National Amyloid Centre, Royal Free Hospital, London, United Kingdom.
  • University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
  • University of Birmingham, Birmingham, United Kingdom.
  • The Binding Site, Birmingham, United Kingdom.
  • University College London Hospital, London, United Kingdom.

ORCID-Profile: Joshua Bomsztyk, Sriram Ravichandran, Oscar Berlanga, Jahanzaib Khwaja, Muhammad U Rauf, Ana Martinez-Naharro, Lucia Venneri, Guy Pratt

Zitieren

APA

Bomsztyk, J., Ravichandran, S., Giles, H. V., Wright, N., Berlanga, O., Khwaja, J., Mahmood, S., Wisniowski, B., Cohen, O., Foard, D., Gilbertson, J., Rauf, M. U., Starr, N., Martinez-Naharro, A., Venneri, L., Whelan, C., Fontana, M., Hawkins, P. N., Gillmore, J. D., …, & Wechalekar, A. D. (2024). Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis. Blood, 143(13), 1259-1268. https://doi.org/10.1182/blood.2023022399

Vancouver

Bomsztyk J, Ravichandran S, Giles HV, Wright N, Berlanga O, Khwaja J, et al. Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis. Blood. 2024;143(13):1259-1268. doi:10.1182/blood.2023022399

BibTeX
@article{Bomsztyk2024,
  author = {Bomsztyk, Joshua and Ravichandran, Sriram and Giles, Hannah V and Wright, Nicola and Berlanga, Oscar and Khwaja, Jahanzaib and Mahmood, Shameem and Wisniowski, Brendan and Cohen, Oliver and Foard, Darren and Gilbertson, Janet and Rauf, Muhammad U and Starr, Neasa and Martinez-Naharro, Ana and Venneri, Lucia and Whelan, Carol and Fontana, Marianna and Hawkins, Philip N and Gillmore, Julian D and Lachmann, Helen and Harding, Stephen and Pratt, Guy and Wechalekar, Ashutosh D},
  title = {Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis},
  journal = {Blood},
  year = {2024},
  volume = {143},
  number = {13},
  pages = {1259--1268},
  doi = {10.1182/blood.2023022399}
}
Kostenlos starten →